Lispro

DRUG15 trials

Sponsors

Sanofi, Eli Lilly and Company, University of Texas Southwestern Medical Center, Biodel, Emory University

Conditions

Diabetes MellitusDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetic NephropathiesHealthy VolunteersHospitalizationHyperglycemiaType 1 Diabetes

Phase 1

A Study of Lispro Formulations in Healthy Participants

CompletedNCT02293551

Eli Lilly and CompanyHealthy Volunteers

Start: 2014-12-31End: 2015-09-30Updated: 2025-09-08

Phase 2

A Study Comparing the Pharmacodynamic Properties of Insulin VIAJECT™, Regular Human Insulin, and Insulin Lispro

CompletedNCT01000922

BiodelDiabetes Mellitus

Start: 2006-06-30End: 2008-01-31Updated: 2015-07-29

Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec

Active, not recruitingNCT06238778

Diasome Pharmaceuticlas, Inc.Diabetes Mellitus, Type 1

Start: 2024-01-23End: 2025-12-31Updated: 2025-08-19

Phase 3

Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents

CompletedNCT00046501

SanofiDiabetes Mellitus

Start: 2002-11-30Target: 250Updated: 2011-01-11

Insulin Glulisine, Insulin Lispro and Insulin Glargine in Type 1 or 2 Diabetes Mellitus

CompletedNCT00467376

SanofiDiabetes Mellitus

Start: 2007-01-31Updated: 2009-09-15

To Evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin During Subcutaneous Insulin Pump Therapy

CompletedNCT01110746

BiodelType 1 Diabetes Mellitus

Start: 2010-02-28End: 2010-06-30Updated: 2015-08-03

Phase 4

The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)

CompletedNCT00279201

Eli Lilly and CompanyDiabetes Mellitus, Type 2

Start: 2005-12-31End: 2009-11-30Updated: 2011-02-21

Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes

WithdrawnNCT00505882

University of Texas Southwestern Medical CenterType 1 Diabetes

Start: 2007-07-31End: 2008-12-31Updated: 2019-01-08

A Study of Postprandial Hyperglycemia in Participants With Type 2 Diabetes

CompletedNCT01159938

Eli Lilly and CompanyDiabetes Mellitus, Type 2

Start: 2010-10-31End: 2013-02-28Updated: 2014-04-03

Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) Therapy in the Inpatients With Type 2 Diabetes

CompletedNCT01378117

Emory UniversityHospitalization, Hyperglycemia, Type 2 Diabetes Mellitus

Start: 2011-08-31End: 2012-06-30Updated: 2018-12-07

Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy

CompletedNCT02690883

Nanfang Hospital, Southern Medical UniversityDiabetic Nephropathies

Start: 2016-04-08End: 2019-12-30Updated: 2020-03-09

Remission Through Early Monitored Insulin Therapy - Duration Month

CompletedNCT03670641

Sandra SobelType 2 Diabetes Mellitus

Start: 2019-03-26End: 2020-07-31Updated: 2021-10-12

SITAgliptin Plus GLARgine to Glycemic Control in the Hospital Setting (SITAGLAR-H)

CompletedNCT05579119

Hospital de Especialidades, Centro Medico Nacional La Raza, Instituto Mexicano del Seguro SocialType 2 Diabetes

Start: 2022-07-06End: 2023-08-24Updated: 2023-09-26

Unknown Phase

Insulin Bolus Required for High Fat Foods in Type 1 Diabetes

CompletedNCT02248454

Joslin Diabetes CenterType 1 Diabetes

Start: 2014-09-30End: 2015-04-30Updated: 2017-04-26

Automated Fully Closed-Loop Insulin Delivery in Type 1 Diabetes With Ultra-Rapid Lispro (ACOLYTE Study)

Manchester University NHS Foundation TrustDiabetes Mellitus, Type 1

Start: 2023-07-21End: 2024-05-01Target: 26Updated: 2023-10-31

Related Papers

Efficacy and safety of sitagliptin with basal-plus insulin regimen versus insulin alone in non-critically ill hospitalized patients with type 2 diabetes: SITA-PLUS hospital trial.

2024-04-031 citations

Insulin exposure mitigates the increase of arterial stiffness in patients with type 2 diabetes and albuminuria: an exploratory analysis.

2019-05-225 citations

How many unpublished studies? ClinicalTrials.gov (n = 2614 studies): diabetes | Closed Studies | Interventional Studies | Phase 3, 4 | Search Date: Oct 27, 2014

Figshare2014-01-01

Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.

2010-05-0133 citations